Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 2/20 | 0.50 |
| ▸ | CDK8 | P49336 | 2/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 4/20 | 0.48 |
| ▸ | KDM4B | O94953 | 1/20 | 0.47 |
| ▸ | KDM5C | P41229 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.44 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112539 | 1.00 | CCNC (0.50) | CCNCCDK8PIK3CBPARP1KDM4B | |
| Hydrochloric Acid SCHEMBL5083661 | 0.98 | CCNC (0.49) | CCNCCDK8PIK3CBPARP1KDM4B | |
| Formic Acid SCHEMBL27859414 | 0.93 | CCNC (0.45) | CCNCCDK8PIK3CBPARP1KDM4B | |
| Butyramide SCHEMBL27726778 | 0.87 | KDM4E (0.43) | CCNCCDK8PIK3CBPARP1KDM4B | |
| SCHEMBL11826813 | 0.83 | MYC (0.40) | CCNCCDK8PIK3CBPARP1KDM4B | |
| SCHEMBL3356107 | 0.83 | UHRF1 (0.50) | CCNCCDK8PIK3CBKDM5CKDM5B | |
| SCHEMBL29527921 | 0.81 | KDM4C (0.61) | KDM4BKDM5CKDM5BUHRF1GABRP | |
| SCHEMBL353289 | 0.81 | KDM4C (0.61) | KDM4BKDM5CKDM5BUHRF1GABRP | |
| SCHEMBL363432 | 0.81 | UHRF1 (0.48) | CCNCCDK8PIK3CBKDM5CKDM5B | |
| SCHEMBL29580893 | 0.81 | UHRF1 (0.48) | CCNCCDK8PIK3CBKDM5CKDM5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | claimed |
| CN-117561250-A | Heterocyclic compound and harmful arthropod control composition containing same | 住友化学株式会社 | 2024-02-13 | — | — | CN | disclosed |
| CN-117545356-A | Heterocyclic compound and method for controlling drug-resistant harmful arthropods by using composition containing same | 住友化学株式会社 | 2024-02-09 | — | — | CN | disclosed |
| CN-117479943-A | EGFR inhibitors and PERK activators in combination therapies and use thereof for treating cancer | 基因泰克公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-116997542-A | Phenylacetic acid derivatives, use thereof and intermediates for the manufacture thereof | 住友化学株式会社 | 2023-11-03 | — | — | CN | disclosed |
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| CN-110612285-B | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2023-04-04 | — | — | CN | disclosed |
| EP-4093400-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | The Trustees of Princeton University (US) | 2022-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250106-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | CCNC 4258/4885CDK8 1453/4885PIK3CB 1100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.